CVS Add to watchlist
$105.90 +0.00 (+0.00%)
Pre-Market: $106.18 +0.28 (+0.26%)
Last updated: Jul 15, 2026 11:55
52-Week Range
$106.18
$58.50 $106.18 $106.93

Fundamentals Overview

CVS Health Corp. is near the high of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 46.3 P/B 1.75 P/S 0.33

Intrinsic value (DCF)

+240.6% upside vs price

Profitability

Net margin 0.7%

Risk (Beta)

0.6 — lower vol

Earnings & growth

EPS $2.29 Rev -5% Profit +0% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 80% confidence Risk: Lower Volatility — Beta 0.6. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +240.6% upside vs price · Analyst grade: B+ · Sentiment improving (1 upgrade) · 3M vs S&P 500: +26.4% · 3M vs Healthcare sector: +29%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$135.48B
P/E (TTM)
46.32
EPS (TTM)
$2.29
Dividend Yield
2.51%
52-Week Range
$58.50 - $106.93
Volume vs Avg
N/A
Beta
0.6

About

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellnes...
Sector: Healthcare
Headquarters: US
Employees: 300,000
IPO Date: Feb 1973
Beta: 0.6 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 8, Market Perform: 2, Outperform: 8, Overweight: 12.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $361.70; current price is $106.18. That’s a +240.6% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 46.32
DCF value (model) $361.70 (240.6% upside)
PEG (TTM) N/A
P/B (TTM) 1.75
P/S (TTM) 0.33
P/FCF (TTM) 18.32
Liquidity & enterprise
Current Ratio (TTM) 0.87
Quick Ratio (TTM) 0.66
Cash Ratio (TTM) 0.11
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 0.72%
Gross margin (TTM) 13.87%
Operating margin (TTM) 1.46%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for CVS.

Analyst Sentiment at a Glance

B+ Sentiment Improving
Buy 8Market Perform 2Outperform 8Overweight 12
1 upgrade, 0 downgrades
Price Target Consensus
Current $106.18
Median $108.00
Consensus $106.57
Low consensus $90.00
High consensus $123.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Wells Fargo maintain Overweight Overweight 2026-07-13
RBC Capital maintain Outperform Outperform 2026-07-09
Cantor Fitzgerald maintain Overweight Overweight 2026-07-07
B of A Securities maintain Buy Buy 2026-06-23
Mizuho maintain Outperform Outperform 2026-06-08
Morgan Stanley maintain Overweight Overweight 2026-06-04
Truist Securities maintain Buy Buy 2026-06-01
Barclays maintain Overweight Overweight 2026-05-26
Mizuho maintain Outperform Outperform 2026-05-20
Morgan Stanley maintain Overweight Overweight 2026-05-14
Bernstein maintain Outperform Outperform 2026-05-13
JP Morgan maintain Overweight Overweight 2026-05-12
TD Cowen maintain Buy Buy 2026-05-11
Wells Fargo maintain Overweight Overweight 2026-05-08
Evercore ISI Group maintain Outperform Outperform 2026-05-07
RBC Capital maintain Outperform Outperform 2026-05-07
UBS maintain Buy Buy 2026-05-07
Barclays maintain Overweight Overweight 2026-05-07
Truist Securities maintain Buy Buy 2026-05-07
Baird maintain Outperform Outperform 2026-04-15
Piper Sandler maintain Overweight Overweight 2026-03-31
Bernstein upgrade Market Perform Outperform 2026-03-12
Argus Research maintain Buy Buy 2026-01-28
B of A Securities maintain Buy Buy 2026-01-27
Bernstein maintain Market Perform Market Perform 2026-01-06
JP Morgan maintain Overweight Overweight 2025-12-17
Bernstein maintain Market Perform Market Perform 2025-12-12
Piper Sandler maintain Overweight Overweight 2025-12-10
Truist Securities maintain Buy Buy 2025-12-10
Barclays maintain Overweight Overweight 2025-12-10